TY  - JOUR 
AU  - Lozano Esteban, Elisa
AU  - Rodríguez Macías, Rocío Isabel
AU  - Monte Río, María Jesús
AU  - Asensio Martín, Maitane
AU  - Carmen Martínez, Sofía del
AU  - Sánchez Vicente, Laura
AU  - Alonso Peña, Marta
AU  - Al Abdulla, Ruba
AU  - Munoz-Garrido, Patricia
AU  - Satriano, Letizia
AU  - O'Rourke, Colm J
AU  - Banales, Jesus M.
AU  - Avila, Matias A.
AU  - Martínez-Chantar, María L.
AU  - Andersen, Jesper B
AU  - Briz Sánchez, Oscar
AU  - García Marín, José Juan
PY  - 2019
UR  - http://hdl.handle.net/10366/155292
AB  - Although the multi-tyrosine kinase inhibitor sorafenib is useful in the treatment of several cancers, cholangiocarcinoma (CCA) is refractory to this drug. Among other mechanisms of chemoresistance, impaired uptake through human organic cation...
LA  - eng
KW  - Chemoresistance
KW  - Cholangiocarcinoma
KW  - Pharmacological treatment
KW  - Octamer Transcription Factor-1
KW  - Cholangiocarcinoma
KW  - DNA Methylation
KW  - Immunoblotting
KW  - Humans
KW  - Cell Line
KW  - Statistics
KW  - Protein Kinase Inhibitors
KW  - Real-Time Polymerase Chain Reaction
KW  - Bile Duct Neoplasms
KW  - Drug Resistance
KW  - RNA
KW  - Down-Regulation
KW  - Genetic Therapy
KW  - Random Allocation
KW  - Rats
KW  - Animals
TI  - Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy
DO  - 10.1002/hep.30656
T2  - Hepatology (Baltimore, Md.)
VL  - 70
M2  - 1246
ER  -